FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1579662013> ?p ?o ?g. }

• W1579662013 abstract "Alzheimer’s disease (AD) continues to disrupt the lives of millions of patients and caregivers around the world. The few drugs currently used for AD have modest effects on the symptoms and do not prevent the progression of the disease into total memory loss and death. With the increase in the number of AD cases and the high social and economical costs of the disease, there is a great need to find disease-modifying therapeutics that target the core pathology of the disease as well as improve the symptoms and the patients’ everyday quality of life. Two types of pathological aggregates are found in AD. The senile plaques are composed of amyloid beta (Aβ), which is cleaved off the amyloid precursor protein (APP) by beta-site APP cleaving enzyme (BACE) and γ-secretase. The other deposits are the neurofibrillary tangles (NFTs), which are mainly composed of hyperphosphorylated tau. These aggregates and factors involved in the production or clearance of Aβ, as well as the phosphorylation of tau are being investigated for potential AD treatments but so far no successful drug candidate has been found. The transcription factor specificity protein 1 (Sp1) has been linked to pathological intermediates in AD. Sp1 regulates the transcription of APP, BACE1, tau and its cyclin dependent kinase-5 (CDK5) activators p39 and p35. Previous experiments from our lab have shown that AD like pathology develops later in vitro and in vivo following early lead (Pb) exposure including elevated levels of SP1, APP, Aβ, tau and CDK5 as well as cognitive decline in mice. Studies from our lab demonstrated that decreasing Sp1 protein (SP1) levels following oral administration of tolfenamic acid to mice was able to reduce APP and Aβ levels and improve cognition. In this dissertation, we first provided an introduction to AD with a review on the role of epigenetics in the disease and the various means by which transcriptional pathways can provide therapeutic alternatives for AD. We then examined the ability of tolfenamic acid to affect the expression of AD targets that are regulated by Sp1 including tau, phosphorylated tau, CDK5 and BACE1 in mice by using Western blot, real time PCR and enzyme activity assays. In addition, we studied the ability of tolfenamic acid to prevent the increase in SP1, APP and Aβ in differentiated neuroblastoma cells that was triggered by prior exposure to Pb. After treatment of cells with Pb, tolfenamic acid or both, we used real time PCR, ELISA and Western blot analyses to examine the effects of both agents on AD related intermediates compared to control. In addition to providing a summary of the current knowledge on epigenetic therapeutic targets for AD, the major findings of this dissertation provide proof that tolfenamic acid was able to decrease the transcription and translation of proteins involved in AD like tau, BACE1 and CDK5 as well as the phosphorylation of tau in mice. Moreover, in differentiated neuroblastoma cells, tolfenamic acid decreased the expression of SP1, APP gene and Aβ which was previously upregulated by Pb. Hence, tolfenamic acid represents a novel oral drug candidate that can be beneficial for AD by affecting both the amyloid and tangle pathology of the disease through a unique transcription driven mechanism." @default.
• W1579662013 created "2016-06-24" @default.
• W1579662013 creator A5090318779 @default.
• W1579662013 date "2020-05-26" @default.
• W1579662013 modified "2023-09-25" @default.
• W1579662013 title "Pharmacodynamic Mechanisms of Tolfenamic Acid Induced SP1 Degradation Relative to Alzheimer's Disease Pathology" @default.
• W1579662013 cites W1217317373 @default.
• W1579662013 cites W1493502680 @default.
• W1579662013 cites W1568595238 @default.
• W1579662013 cites W1592880910 @default.
• W1579662013 cites W1693568153 @default.
• W1579662013 cites W1964474096 @default.
• W1579662013 cites W1970992656 @default.
• W1579662013 cites W1975040221 @default.
• W1579662013 cites W1977879318 @default.
• W1579662013 cites W1978276744 @default.
• W1579662013 cites W1985053970 @default.
• W1579662013 cites W1994336523 @default.
• W1579662013 cites W1995515835 @default.
• W1579662013 cites W1997322102 @default.
• W1579662013 cites W1998047781 @default.
• W1579662013 cites W1999973557 @default.
• W1579662013 cites W2000706612 @default.
• W1579662013 cites W2002839290 @default.
• W1579662013 cites W2003283600 @default.
• W1579662013 cites W2019036379 @default.
• W1579662013 cites W2021370614 @default.
• W1579662013 cites W2022231372 @default.
• W1579662013 cites W2022969837 @default.
• W1579662013 cites W2025405517 @default.
• W1579662013 cites W2032920422 @default.
• W1579662013 cites W2033382511 @default.
• W1579662013 cites W2035613313 @default.
• W1579662013 cites W2036755018 @default.
• W1579662013 cites W2038838498 @default.
• W1579662013 cites W2041231034 @default.
• W1579662013 cites W2045394310 @default.
• W1579662013 cites W2046847750 @default.
• W1579662013 cites W2046972756 @default.
• W1579662013 cites W2048560678 @default.
• W1579662013 cites W2051067435 @default.
• W1579662013 cites W2067915140 @default.
• W1579662013 cites W2068212369 @default.
• W1579662013 cites W2075725519 @default.
• W1579662013 cites W2076724866 @default.
• W1579662013 cites W2081030499 @default.
• W1579662013 cites W2085693623 @default.
• W1579662013 cites W2093426751 @default.
• W1579662013 cites W2096410114 @default.
• W1579662013 cites W2096749156 @default.
• W1579662013 cites W2099236418 @default.
• W1579662013 cites W2099463388 @default.
• W1579662013 cites W2103440561 @default.
• W1579662013 cites W2115688283 @default.
• W1579662013 cites W2118539817 @default.
• W1579662013 cites W2124726981 @default.
• W1579662013 cites W2125985978 @default.
• W1579662013 cites W2129489564 @default.
• W1579662013 cites W2132259157 @default.
• W1579662013 cites W2133778193 @default.
• W1579662013 cites W2135309154 @default.
• W1579662013 cites W2148473649 @default.
• W1579662013 cites W2149631100 @default.
• W1579662013 cites W2156093068 @default.
• W1579662013 cites W2156524025 @default.
• W1579662013 cites W2159677246 @default.
• W1579662013 cites W2164829288 @default.
• W1579662013 cites W2165165188 @default.
• W1579662013 cites W2170241782 @default.
• W1579662013 cites W2318028690 @default.
• W1579662013 cites W2318447699 @default.
• W1579662013 cites W2324095269 @default.
• W1579662013 cites W2406708845 @default.
• W1579662013 doi "https://doi.org/10.23860/diss-adwan-lina-2013" @default.
• W1579662013 hasPublicationYear "2020" @default.
• W1579662013 type Work @default.
• W1579662013 sameAs 1579662013 @default.
• W1579662013 citedByCount "0" @default.
• W1579662013 crossrefType "dissertation" @default.
• W1579662013 hasAuthorship W1579662013A5090318779 @default.
• W1579662013 hasBestOaLocation W15796620131 @default.
• W1579662013 hasConcept C121738310 @default.
• W1579662013 hasConcept C142724271 @default.
• W1579662013 hasConcept C150903083 @default.
• W1579662013 hasConcept C15744967 @default.
• W1579662013 hasConcept C169760540 @default.
• W1579662013 hasConcept C184235292 @default.
• W1579662013 hasConcept C185592680 @default.
• W1579662013 hasConcept C207001950 @default.
• W1579662013 hasConcept C207886595 @default.
• W1579662013 hasConcept C2779134260 @default.
• W1579662013 hasConcept C31705614 @default.
• W1579662013 hasConcept C502032728 @default.
• W1579662013 hasConcept C55493867 @default.
• W1579662013 hasConcept C68026918 @default.
• W1579662013 hasConcept C71924100 @default.
• W1579662013 hasConcept C82495950 @default.
• W1579662013 hasConcept C86803240 @default.
• W1579662013 hasConcept C97029542 @default.
• W1579662013 hasConcept C98274493 @default.

• next